However, this observation was not confirmed in randomized phase II or III trials, where PTEN deficiency assessed by immunohistochemistry was not found to preclude a response to Lapatinib plus endocrine therapy or Lapatinib plus Paclitaxel in metastatic BC [31,45]. The gene discussed is PTEN; the disease is breast cancer.